U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H24N4O3
Molecular Weight 320.3868
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DENBUFYLLINE

SMILES

CCCCN1C2=C(N(CC(C)=O)C=N2)C(=O)N(CCCC)C1=O

InChI

InChIKey=HJPRDDKCXVCFOH-UHFFFAOYSA-N
InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3

HIDE SMILES / InChI

Description

Denbufylline is a selective xanthine derivative that inhibits PDE IV and has bronchodilatory properties. Shown to exhibit negative inotropic effects by acting on verapamil-sensitive sites of Ca2+ channels in guinea pig ventricle papillary muscle independently of its PDE inhibitory activity. Denbufylline, a selective type 4 phosphodiesterase (PDE-4) inhibitor, is a potent activator of the hypothalamo-pituitary-adrenal (HPA) axis when given orally or intraperitoneally (i.p.) to adult male rats. Denbufylline was being developed as an agent for the therapy of dementia.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.3 µM [IC50]
1.5 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
The patients with dementia of the Alzheimer type (DAT) were randomly allocated to denbufylline 25, 50 or 100 mg or to placebo given twice daily for 16 weeks.
Route of Administration: Oral
In Vitro Use Guide
Cyclic AMP PDE activity of human eosinophil homogenates was inhibited by denbufylline (IC50 = 360 nM).